Second LongevityTech.fund now accepting new investors

LongevityTech.Fund is now accepting new investors with a maximum fund size of US$100m.

With this second funding, LongevityTech.fund aims to support early stage longevity startups with high growth potential.

Closing in October 2022, the second fund follows a first one concluded with over 40 investments, including one exit and one IPO placing the company firmly in the world’s top five most active longevity investors.

Petr Sramek, team lead of the fund, said: “The science and industry of longevity is experiencing exponential growth, and we expect massive hype after 2025 when we plan to nurture and gradually exit our portfolio companies.

“Because longevity solutions bring real value to the global population, it will gradually become one of the largest and most impactful industries.”

LongevityTech.fund’s investments fall into three broad categories – therapeutics and the enabling platform technologies, biomarker discovery and diagnostics including companion diagnostics, and industry accelerators.

The investment platform’s aim is to support and capture the innovation wave through seed and pre-seed stage investments. Its scientific board spans an interdisciplinary mix of established leaders in the filed.

It also provides proactive portfolio support and mentoring with a world-class network of scientists and investors, IP and commercialisation support and exit opportunities. 

Apart from investing in external companies, LongevityTech.fund is also incubating and building the world’s first extensive longevity ecosystem. 

Its companies are incorporated in the US, headquartered in Palo Alto but active around the world.

The platform seeks tech entrepreneurs with a successful track record of startup scaling in various fields like life-science, B2B or B2C SasS, med-tech or hospitality.